<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>生物制药小编 | wechat-feeds</title><link>http://MzU3Nzg4NzQyNg.favicon.privacyhide.com/favicon.ico</link><description>“新起点，再出发”——生物医药小编与您共同关注生物制药行业热点。</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 23 Apr 2021 10:18:46 +0800</pubDate><image><url>http://MzU3Nzg4NzQyNg.favicon.privacyhide.com/favicon.ico</url><title>生物制药小编 | wechat-feeds</title><link>http://MzU3Nzg4NzQyNg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>斯鲁利单抗上市申请拟纳入优先审评，国内PD-1疗法即将进入不区分癌种时代</title><link>https://mp.weixin.qq.com/s/lXCWfCudep1wAtU5pEwu8A</link><description></description><content:encoded><![CDATA[斯鲁利单抗上市申请拟纳入优先审评，国内PD-1疗法即将进入不区分癌种时代]]></content:encoded><pubDate>Thu, 22 Apr 2021 21:51:25 +0800</pubDate></item><item><title>【火力全开，集赞即赠】QbD2021第二届生物药质量科学大会全新议程发布！</title><link>https://mp.weixin.qq.com/s/Mv0r_QttEWSVwX7kGRJWLw</link><description></description><content:encoded><![CDATA[【火力全开，集赞即赠】QbD2021第二届生物药质量科学大会全新议程发布！]]></content:encoded><pubDate>Thu, 22 Apr 2021 21:51:25 +0800</pubDate></item><item><title>国内首款：爱思迈申报CD3/CD20双抗</title><link>https://mp.weixin.qq.com/s/7VwRmCy-MSfizNXWU9XHUg</link><description></description><content:encoded><![CDATA[国内首款：爱思迈申报CD3/CD20双抗]]></content:encoded><pubDate>Thu, 22 Apr 2021 13:10:43 +0800</pubDate></item><item><title>抗体药体外免疫活性质检标杆——ADCC</title><link>https://mp.weixin.qq.com/s/r_dq9Lz6Nsvk69bHwPSGSA</link><description></description><content:encoded><![CDATA[抗体药体外免疫活性质检标杆——ADCC]]></content:encoded><pubDate>Thu, 22 Apr 2021 13:10:43 +0800</pubDate></item><item><title>2021招聘！复旦基础医学院&amp;上海合成免疫工程技术研究中心</title><link>https://mp.weixin.qq.com/s/Zh2im5Nsp6lvbPPkG-PqhQ</link><description></description><content:encoded><![CDATA[2021招聘！复旦基础医学院&上海合成免疫工程技术研究中心]]></content:encoded><pubDate>Thu, 22 Apr 2021 13:10:43 +0800</pubDate></item><item><title>信达肿瘤选择性CD47/PD-L1双抗</title><link>https://mp.weixin.qq.com/s/eOPU1fmXlfMYIjbNVKpWFg</link><description></description><content:encoded><![CDATA[信达肿瘤选择性CD47/PD-L1双抗]]></content:encoded><pubDate>Tue, 20 Apr 2021 16:02:40 +0800</pubDate></item><item><title>课程预告 | 后PD1时代——人源化小鼠在靶向NK细胞药物开发中的应用</title><link>https://mp.weixin.qq.com/s/ivqayKVH4Ox8q0wJCKIyXg</link><description></description><content:encoded><![CDATA[课程预告 | 后PD1时代——人源化小鼠在靶向NK细胞药物开发中的应用]]></content:encoded><pubDate>Tue, 20 Apr 2021 16:02:40 +0800</pubDate></item><item><title>细胞基因产品质量研究及申报注册</title><link>https://mp.weixin.qq.com/s/6K5grDJrEYskKtcKHa8wmg</link><description></description><content:encoded><![CDATA[细胞基因产品质量研究及申报注册]]></content:encoded><pubDate>Tue, 20 Apr 2021 16:02:40 +0800</pubDate></item><item><title>Self Renew｜GPCR相关抗体的开发——不再单调的MOA</title><link>https://mp.weixin.qq.com/s/nDLiO8RNFjJiOo_klNvGrA</link><description></description><content:encoded><![CDATA[Self Renew｜GPCR相关抗体的开发——不再单调的MOA]]></content:encoded><pubDate>Tue, 20 Apr 2021 08:47:39 +0800</pubDate></item><item><title>本周六盛大开启 | 2021PVcon生物制品安全与工艺大会</title><link>https://mp.weixin.qq.com/s/tZwTJfeZfThvnO8DdtKhVA</link><description></description><content:encoded><![CDATA[本周六盛大开启 | 2021PVcon生物制品安全与工艺大会]]></content:encoded><pubDate>Tue, 20 Apr 2021 08:47:39 +0800</pubDate></item><item><title>FDA是如何审评药品的</title><link>https://mp.weixin.qq.com/s/UFC6HSmwV9b9dxv76AXUTg</link><description></description><content:encoded><![CDATA[FDA是如何审评药品的]]></content:encoded><pubDate>Tue, 20 Apr 2021 08:47:39 +0800</pubDate></item><item><title>Schlafen 5：治疗胰腺癌的新靶点</title><link>https://mp.weixin.qq.com/s/xo-S9GPev6slQDSRK9Ui7A</link><description></description><content:encoded><![CDATA[Schlafen 5：治疗胰腺癌的新靶点]]></content:encoded><pubDate>Sun, 18 Apr 2021 20:32:16 +0800</pubDate></item><item><title>Twist Bioscience「谱写未来-亚太区专场」线上会议诚邀您参加</title><link>https://mp.weixin.qq.com/s/mmfUvuqRnis_2WbPwONSdA</link><description></description><content:encoded><![CDATA[Twist Bioscience「谱写未来-亚太区专场」线上会议诚邀您参加]]></content:encoded><pubDate>Sun, 18 Apr 2021 20:32:16 +0800</pubDate></item><item><title>2021复旦大学基础医学院招聘开始啦！</title><link>https://mp.weixin.qq.com/s/tbhlQy0CNE6hLQHZSBenDg</link><description></description><content:encoded><![CDATA[2021复旦大学基础医学院招聘开始啦！]]></content:encoded><pubDate>Sun, 18 Apr 2021 20:32:16 +0800</pubDate></item><item><title>诺华（Novartis）——天价药合理且合法？</title><link>https://mp.weixin.qq.com/s/dlvvGvoibZ3IulDMRVYTBw</link><description></description><content:encoded><![CDATA[诺华（Novartis）——天价药合理且合法？]]></content:encoded><pubDate>Sat, 17 Apr 2021 19:49:00 +0800</pubDate></item><item><title>买家团火热来袭：你的渠道够强吗？</title><link>https://mp.weixin.qq.com/s/JibfojDUsS3YGGFWI9YWFA</link><description></description><content:encoded><![CDATA[买家团火热来袭：你的渠道够强吗？]]></content:encoded><pubDate>Sat, 17 Apr 2021 19:49:00 +0800</pubDate></item><item><title>做中国生物医药的忠实记录者</title><link>https://mp.weixin.qq.com/s/UouMgDdStjrP8MN-NWRE5w</link><description></description><content:encoded><![CDATA[做中国生物医药的忠实记录者]]></content:encoded><pubDate>Sat, 17 Apr 2021 19:49:00 +0800</pubDate></item><item><title>双特异性抗体：on-target off-tumor毒性及克服策略</title><link>https://mp.weixin.qq.com/s/6mUjx3lHw4KivmuA3Ff-qQ</link><description></description><content:encoded><![CDATA[双特异性抗体：on-target off-tumor毒性及克服策略]]></content:encoded><pubDate>Fri, 16 Apr 2021 19:25:47 +0800</pubDate></item><item><title>佰傲严选：亮剑吧！您的分析仪器！</title><link>https://mp.weixin.qq.com/s/V6zouh-X1N5Ibti_CFabjQ</link><description></description><content:encoded><![CDATA[佰傲严选：亮剑吧！您的分析仪器！]]></content:encoded><pubDate>Fri, 16 Apr 2021 19:25:47 +0800</pubDate></item><item><title>杨森Bipod高通量双抗开发平台</title><link>https://mp.weixin.qq.com/s/T72LX0A-8FdxZUlB0myUHg</link><description></description><content:encoded><![CDATA[杨森Bipod高通量双抗开发平台]]></content:encoded><pubDate>Thu, 15 Apr 2021 17:06:00 +0800</pubDate></item></channel></rss>